GlobalData’s Key Thoughts From World EPA Congress 2026

Why It Matters

The discussions highlight how regulatory and policy shifts are redefining pharmaceutical pricing, access, and development timelines, forcing companies to adapt quickly or risk market share loss.

Key Takeaways

• MFN policy reshapes global market access strategies.
• US tariff shifts demand proactive pricing intelligence.
• AI adoption stalls; human oversight remains essential.
• JCA legislation adds complexity to oncology drug assessments.
• Portfolio-wide launch planning supersedes indication sequencing.

Pulse Analysis

The EPA congress underscored a growing consensus that market instability is now the norm for pharma and biotech firms. Participants dissected the Most Favored Nation (MFN) policy, noting its potential to compress margins and reshape cross‑border pricing models. Simultaneously, shifting US tariff regimes were flagged as a catalyst for companies to adopt real‑time intelligence platforms, ensuring they can pre‑emptively adjust pricing, negotiate risk‑sharing agreements, or even delay launches to protect portfolio value.

Artificial intelligence dominated the agenda, with 23 dedicated sessions revealing both enthusiasm and caution. While AI tools are accelerating clinical trial design, commercial forecasting, and health‑technology assessment (HTA) dossiers, speakers warned that data hallucinations and ethical compliance still demand human oversight. The gap between AI promise and practical uptake suggests a hybrid approach will dominate the near term, where algorithmic speed is balanced by rigorous validation and transparent governance.

The introduction of the EU Joint Clinical Assessment (JCA) framework adds another layer of complexity, especially for oncology and advanced therapy medicinal products. Early data show that multiple PICO submissions per drug slow assessment timelines, and adoption varies across member states. Companies must now craft dossier strategies that satisfy a unified EU review while accommodating divergent national implementations. This dual pressure pushes firms toward portfolio‑wide launch planning, moving beyond traditional indication sequencing to optimize market entry across heterogeneous regulatory environments.